| Maria Cecilia Crisanti, MD | |
|
2314 Sassafras St, Suite 200, Erie, PA 16502-2722 | |
| (814) 454-4484 | |
| (814) 452-1809 |
| Full Name | Maria Cecilia Crisanti |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 2314 Sassafras St, Erie, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265724181 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD453069 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bellevue Hospital Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Westchester Medical Group Pc | 6406752963 | 405 |
News Archive
The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.
Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.
Researchers at the University of Waterloo's Institute for Quantum Computing (IQC) have developed a new quantum sensor that could mean a significant advancement in 3D imaging and monitoring for cancer patients.
› Verified 8 days ago
| Entity Name | Westchester Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881653822 PECOS PAC ID: 6406752963 Enrollment ID: O20031208000533 |
News Archive
The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.
Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.
Researchers at the University of Waterloo's Institute for Quantum Computing (IQC) have developed a new quantum sensor that could mean a significant advancement in 3D imaging and monitoring for cancer patients.
› Verified 8 days ago
| Entity Name | St Joseph's Hospital Yonkers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356316921 PECOS PAC ID: 0547156176 Enrollment ID: O20040223000340 |
News Archive
The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.
Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.
Researchers at the University of Waterloo's Institute for Quantum Computing (IQC) have developed a new quantum sensor that could mean a significant advancement in 3D imaging and monitoring for cancer patients.
› Verified 8 days ago
| Entity Name | Sun River Health Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568526838 PECOS PAC ID: 6608783568 Enrollment ID: O20040714000375 |
News Archive
The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.
Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.
Researchers at the University of Waterloo's Institute for Quantum Computing (IQC) have developed a new quantum sensor that could mean a significant advancement in 3D imaging and monitoring for cancer patients.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maria Cecilia Crisanti, MD 2314 Sassafras St, Suite 200, Erie, PA 16502-2722 Ph: (814) 454-4484 | Maria Cecilia Crisanti, MD 2314 Sassafras St, Suite 200, Erie, PA 16502-2722 Ph: (814) 454-4484 |
News Archive
The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.
Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.
Researchers at the University of Waterloo's Institute for Quantum Computing (IQC) have developed a new quantum sensor that could mean a significant advancement in 3D imaging and monitoring for cancer patients.
› Verified 8 days ago
Mrs. Marsha Sigrid Dietrich-mclean, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 State St, Erie, PA 16550 Phone: 814-877-4922 Fax: 814-877-3622 | |
Matthew Heitzenrater, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 State St Ste 401, Erie, PA 16507 Phone: 814-877-5333 Fax: 814-877-5329 | |
Dr. Mary Katherine Lasher, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 2501 W 12th St Ste C4, Erie, PA 16505 Phone: 814-461-6626 | |
Matthew Alan Potts, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5515 Peach St, Erie, PA 16509 Phone: 814-864-4031 | |
David Kruszewski, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3125 French St, Erie, PA 16504 Phone: 814-456-2047 | |
Harry Louis Haus, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3823 W 12th St, Erie, PA 16505 Phone: 814-490-3728 | |
Cecilia T. Urquico, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2501 W 12th St, Suite 1, Erie, PA 16505 Phone: 814-806-1144 Fax: 814-833-0659 |